Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31087387 | 0.88 | MGAM (0.51) | EGFRKDM1AMAOAMGAMMAPT | |
| SCHEMBL383854 | 0.87 | MAPT (0.46) | EGFRKDM1AMAPTHTTNTRK1 | |
| SCHEMBL424353 | 0.83 | HTT (0.62) | EGFRKDM1AMAOAMGAMMAPT | |
| SCHEMBL383072 | 0.82 | HTT (0.61) | EGFRKDM1AMAOAMGAMMAPT | |
| Citpressine Ii SCHEMBL29711402 | 0.77 | CTSV (0.52) | EGFRKDM1AMAOAMGAMMAPT | |
| SCHEMBL24155343 | 0.76 | L3MBTL1 (0.52) | MAPTHTTNTRK1ACHEL3MBTL1 | |
| SCHEMBL383447 | 0.75 | NTRK1 (0.36) | EGFRKDM1ANTRK1L3MBTL1MAT2A | |
| SCHEMBL26229312 | 0.72 | NTRK1 (0.50) | KDM1AMAPTNTRK1L3MBTL1MAT2A | |
| SCHEMBL18288081 | 0.72 | L3MBTL1 (0.60) | EGFRMAOAMAPTHTTNTRK1 | |
| SCHEMBL8576451 | 0.70 | EGFR (1.00) | EGFRMAOAMAPTACHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330456-B9 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1330456-B9 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1330456-B1 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2011-06-15 | — | — | EP | disclosed |
| EP-1330456-B1 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2011-06-15 | — | — | EP | disclosed |
| US-7115619-B2 | N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | TERT, MKI67, NQO2 | EGFR 864/4885KDM1A 547/4885MAOA 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.